Comprehensive financial assistance is available for eligible individuals
The Amylyx Care Team strives to find affordable solutions through 3 key programs:
$0 Co-Pay Program*
If you are commercially insured with private insurance (not Medicare or Medicaid or any other federal- or state-funded insurance program), you may be eligible for our co-pay assistance program. Your ACT Care Coordinator can help see if you qualify for a $0 co-pay.
Interim Access Program
We can assess your eligibility to receive up to 2 months of RELYVRIO while you are waiting for your insurance company to approve your treatment. This program is available on a case-by-case basis if you’ve been prescribed RELYVRIO for the first time and are commercially insured.
Patient Assistance Program
If you do not have insurance or do not have insurance that covers your treatment, the ACT Patient Assistance Program may be able to assist you. ACT team members can work with you to determine eligibility.
*Out-of-pocket costs related to medication, appointments, evaluations, testing, or other related services are not covered by the RELYVRIO Co-Pay Program. The RELYVRIO Co-Pay Program is not available for prescriptions purchased under Medicare, Medicaid, TRICARE, or other federal- and state-funded programs. Amylyx reserves the right to amend or terminate the Program at any time without notice. Co-pay amounts after applying co-pay assistance may depend on the patient’s insurance plan and may vary. The RELYVRIO Co-Pay Program is intended to help individuals afford RELYVRIO.
Find out more about the ACT Support Program
RESOURCES TO HELP YOU LEARN MORE
RELYVRIO Overview Brochure
More information about treatment with RELYVRIO
What to Expect
A handy guide to getting started with RELYVRIO
Directions for Use
A convenient reference for taking RELYVRIO
Answers to frequently asked questions about RELYVRIO
A recording of a live webinar for the ALS community
Useful information about the Amylyx Care Team (ACT)
Important information on RELYVRIO
STAY IN THE KNOW
Fill out the form below to stay informed and receive the latest information on RELYVRIO.
A HEARTFELT THANKS
Amylyx wants to thank all of you in the ALS community, including clinical trial participants, their families, investigators, sites of the trial, and individuals who have given us feedback along the way. We’re dedicated to representing the ALS community in everything we do. We know that we couldn’t have achieved any of this without you.